Sign in

NCT06010641Recruiting

Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3)

Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3): a Prospective, Randomized, Open-label, Blinded-endpoint, Multi-center Trial

Source: ClinicalTrials.gov · Last updated 27 Apr 2026

Brief summary (registry, in English)

The effect of head position as a nonpharmacological therapy on acute ischemic stroke (AIS) remains inconclusive. Recent HOPES2 (Head dOwn-Position for acutE moderate ischemic Stroke with large artery atherosclerosis) suggest the safety, feasibility, and potential benefit of the head-down position (HDP) in acute ischemic stroke. The current study aims to investigate the efficacy and safety of HDP in acute moderate ischemic stroke patients with large artery atherosclerosis.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
600 (estimated)
First submitted
20 Aug 2023
Start date
10 Jan 2024
Primary completion date
30 Oct 2027
Lead sponsor
General Hospital of Shenyang Military Region
Diseases
Stroke
NCT number
NCT06010641

What you commit to

  • Study type: Interventional
  • Planned participants: 600
  • From 10 Jan 2024 to the primary completion date, 30 Oct 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous history of intracerebral hemorrhage within 1 year;

Other illness

  • Pre-stroke disability (mRS≥3);
  • Hemorrhagic stroke or combined ischemic and hemorrhagic stroke;
  • Serious comorbidity, such as liver or kidney insufficiency, malignant tumor, etc;
  • Other stroke etiologies, such as cardiogenic embolism, arteritis, arterial dissection, moyamoya disease, etc;
  • Any contraindication to head-down position (e.g. active vomiting, pneumonia, uncontrolled heart failure);
  • Severe uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 100 mmHg);
  • Cardiac insufficiency (NYHA Class ≥II);
  • Comorbidity with other serious diseases;

Other

  • Patients with disturbance of consciousness;
  • Patients who plan to undergo or have completed thrombolysis or mechanical thrombectomy;
  • Planned carotid or intracranial revascularization within 3 months;
  • Pregnant or lactating women;
  • Participating in other clinical trials within 3 months;
  • Patients not suitable for the study considered by researcher.

Who the study is looking for

  • Age ≥ 18 years old
  • Acute ischemic stroke confirmed by NCCT or MRI;
  • Moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours of onset, or progressing from mild (NIHSS ≤ 5) to moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours, requiring ≥ 4 point increase in NIHSS score although the onset time is beyond 24 hours;
  • Probable large artery atherosclerosis etiology based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (responsible artery stenosis ≥ 50% or occlusion);
  • Anterior circulation stroke (internal carotid artery, M1 or M2 of middle cerebral artery);
  • First stroke onset or past stroke without obvious neurological deficit (mRS≤2);
  • Signed informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Neurology, General Hospital of Northern Theater Command
Coordinator of this site? Confirm its status
ShenyangChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.